Pharmacovigilance for antiretroviral drugs in Africa: Lessons from a study in Abidjan, Cote d'Ivoire

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 12, 2011, Pages 1303-1310

  Jaquet, Antoine ^a   Djima, Mariam Mama ^a,b   Coffie, Patrick ^a,b   Kacou, Henri Die ^c   Eholie, Serge P ^b   Messou, Eugene ^d   Minga, Albert ^e   Guehi, Calixte ^b   Yavo, Jean Claude ^c   Bissagnene, Emmanuel ^b   Dabis, Francois ^a   Ekouevi, Didier K ^a,b  

^a INSERM   (France)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE TREICHVILLE   (Côte d’Ivoire)

^c CHU de Cocody   (Côte d’Ivoire)

^d ACONDA   (Côte d’Ivoire)

^e Centre Médical de Suivi de Donneurs de Sang CNTS PRIMO CI   (Côte d’Ivoire)

Author keywords

Antiretroviral; HIV AIDS; Pharmacovigilance; Sub Saharan Africa

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; AFRICA; ARTICLE; CARDIOTOXICITY; CHEST TIGHTNESS; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EYE INJURY; FEMALE; GASTROINTESTINAL DISEASE; HEALTH SURVEY; HEMATOLOGIC DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; KNOWLEDGE; LACTIC ACIDOSIS; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; NEPHROTIC SYNDROME; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; SKIN MANIFESTATION;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-HIV AGENTS; COTE D'IVOIRE; DATABASES, FACTUAL; DRUG MONITORING; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PHARMACOVIGILANCE; PHYSICIANS; QUESTIONNAIRES; RETROSPECTIVE STUDIES;

EID: 81955163009     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2182     Document Type: Article

References (26)

1. UNAIDS. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2010. UNAIDS: Geneva, 2010. [18 October 2010].
2. Eholie SP, Tanon KA, Folquet-Amorissani M, et al. Impact of access to antiretroviral therapy in Cote d'Ivoire. Med Trop (Mars) 2009 Oct; 69(5): 520-524.
3. Bashi J, Balestre E, Messou E, et al. Time trends in demographic and clinical characteristics of adult patients on HAART initiation in West Africa [French]. Med Mal Infect 2009 Aug; 40(8): 449-455.
4. Messou E, Anglaret X, Duvignac J, et al. Antiretroviral treatment changes in adults from Cote d'Ivoire: the roles of tuberculosis and pregnancy. AIDS 2010 Jan 2; 24(1): 93-99.
5. Braitstein P, Ayuo P, Mwangi A, et al. Sustainability of first-line antiretroviral regimens: findings from a large HIV treatment program in western Kenya. J Acquir Immune Defic Syndr 2010 Feb 1; 53(2): 254-259.
6. Olsson S (ed.). National Pharmacovigilance Systems. Country Profiles and Overview (2nd edn). The Uppsala Monitoring Centre: S-75103 Uppsala, Sweden, 1999.
7. Dodoo AN, Fogg C, Asiimwe A, et al. Pattern of drug utilization for treatment of uncomplicated malaria in urban Ghana following national treatment policy change to artemisinin-combination therapy. Malar J 2009; 8(5): 2.
8. Mehta U, Durrheim D, Mabuza A, Blumberg L, Allen E, Barnes KI. Malaria pharmacovigilance in Africa: lessons from a pilot project in Mpumalanga Province, South Africa. Drug Saf 2007; 30(10): 899-910.
9. Simooya O. The WHO 'Roll Back Malaria Project': planning for adverse event monitoring in Africa. Drug Saf 2005; 28(4): 277-286.
10. Ekouevi DK, Balestre E, Ba-Gomis FO, et al. Low retention of HIV-infected patients on antiretroviral therapy in II clinical centres in West Africa. Trop Med Int Health 2010 Jun; 15: 34-42.
11. Oshikoya KA, Awobusuyi JO. Perceptions of doctors to adverse drug reaction reporting in a teaching hospital in Lagos, Nigeria. BMC Clin Pharmacol 2009; 9(11): 14.
12. The Upssala Monitoring Center. WHO Programme for International Drug Monitoring. [18 October 2010].
13. Adverse Drug Reaction and Medicine Review Committee. Evaluation of a training course on pharmacovigilance in Sub-Saharan Africa. Pharmacoepidemiol Drug Saf 2000 Mar; 9(2): 133-138.
14. Ball D, Tisocki T. Adverse drug reaction reporting by general medical practitioners and retail pharmacists in Harare--a pilot study. Cent Afr J Med 1998 Aug; 44(8): 190-195.
15. Sevene E, Mariano A, Mehta U, et al. Spontaneous adverse drug reaction reporting in rural districts of Mozambique. Drug Saf 2008; 31(10): 867-876.
16. Bukirwa H, Nayiga S, Lubanga R, et al. Pharmacovigilance of antimalarial treatment in Uganda: community perceptions and suggestions for reporting adverse events. Trop Med Int Health 2008 Sep; 13(9): 1143-1152.
17. Talisuna AO, Staedke SG, D'Alessandro U. Pharmacovigilance of antimalarial treatment in Africa: is it possible? Malar J 2006; 5: 50.
18. Forna F, Liechty CA, Solberg P, et al. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 2007 Apr 1; 44(4): 456-462.
19. Boulle A, Orrel C, Kaplan R, et al. Substitutions due to antiretroviral toxicity or contraindication in the first 3years of antiretroviral therapy in a large South African cohort. Antivir Ther 2007; 12(5): 753-760.
20. Ministère de la Santé et de l'Hygiène Publique de la République de Côte d'Ivoire, Programme National de Prise en Charge des Personnes Vivant avec le VIH. Atelier technique de révision des Stratégies thérapeutiques antirétrovirales en Côte d'Ivoire, Bassam, 12 - 15 février, 2008. Rapport final.
21. Danel C, Moh R, Anzian A, et al. Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa. J Acquir Immune Defic Syndr 2006 May; 42(1): 29-35.
22. van Griensven J, Zachariah R, Rasschaert F, Mugabo J, Atte EF, Reid T. Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda. Trans R Soc Trop Med Hyg 2010 Feb; 104(2): 148-153.
23. Keiser O, Anastos K, Schechter M, et al. Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health 2008 Jul; 13(7): 870-879.
24. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach (2010 revision). WHO: Geneva, 2010. [18 October 2010].
25. Lichtenstein KA, Armon C, Baron A, Moorman AC, Wood KC, Holmberg SD. Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin Infect Dis 2005 Jan 1; 40(1): 148-157.
26. WHO. A practical handbook on the pharmacovigilance of antiretroviral medicines. WHO: Geneva, 2009. [18 October 2010].